Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Oncopeptides AB
Sponsor:
Information provided by (Responsible Party):
Oncopeptides AB
ClinicalTrials.gov Identifier:
NCT01897714
First received: July 9, 2013
Last updated: October 15, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2017
  Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)